Creating a new delivery system for cancer treatment drugs
Development of Biodegradable Nanocarrier for Improved Co-delivery of PARPi and DNMTi
This study is testing a new way to deliver cancer treatment drugs directly to tumors using a special biodegradable carrier, which could make the treatments work better and cause fewer side effects for patients with hard-to-treat cancers.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Nebraska Medical Center NIH-funded |
| Lab location | 1 site (Omaha, United States) |
| Project ID | NIH-11170785 on NIH RePORTER |
What this research studies
This research focuses on developing a biodegradable nanocarrier that can effectively deliver two types of cancer treatment drugs, PARP inhibitors and DNMT inhibitors, to tumors. The approach aims to enhance the effectiveness of these drugs, particularly for cancers that do not respond well to standard treatments. By using a specially designed nanocarrier, the research seeks to improve the drugs' bioavailability and reduce side effects, making treatment safer and more effective for patients. The study involves advanced techniques to ensure that the drugs are delivered precisely to the tumor site, maximizing their impact while minimizing harm to healthy tissues.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with specific types of cancers that may benefit from the combination of PARP inhibitors and DNMT inhibitors.
Not a fit: Patients whose cancers are not responsive to PARP inhibitors or DNMT inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer cancer treatments for patients, particularly those with hard-to-treat tumors.
How similar studies have performed: Previous research has shown promise in using nanocarriers for drug delivery in cancer treatment, indicating that this approach may lead to significant advancements.
Where this research is happening
Omaha, United States
- University of Nebraska Medical Center — Omaha, United States (Active)
Researchers
- Principal investigator: Sun, Jingjing — University of Nebraska Medical Center
- Study coordinator: Sun, Jingjing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.